New combo therapy tested for Tough-to-Treat breast cancer
NCT ID NCT05501769
Summary
This early-stage study tested the safety of combining two drugs, ARV-471 and everolimus, for people with advanced breast cancer that has stopped responding to standard hormone therapies. It involved 32 participants to find the safest and most effective dose for future research. The main goal was to understand the side effects and determine if the combination is safe enough to study further.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
San Diego, California, 92037, United States
-
Clinical Trial Site
Santa Monica, California, 90404, United States
-
Clinical Trial Site
Washington D.C., District of Columbia, 20007, United States
-
Clinical Trial Site
Lake Mary, Florida, 32746, United States
-
Clinical Trial Site
Ann Arbor, Michigan, 48109, United States
-
Clinical Trial Site
Nashville, Tennessee, 37203, United States
-
Clinical Trial Site
Barcelona, 08028, Spain
-
Clinical Trial Site
Madrid, 28034, Spain
-
Clinical Trial Site
Valencia, 46018, Spain
Conditions
Explore the condition pages connected to this study.